Novo Nordisk A/S - Share repurchase programme
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.
Since the announcement as of 22 February 2010, the following transactions have
been made under the programme:
Number of Average Transaction value,
shares purchase price DKK
Accumulated, last 1,305,000 496,879,259
announcement
22 February 2010 85,000 396.5120 33,703,520
23 February 2010 155,000 389.5312 60,377,336
24 February 2010 91,000 391.8990 35,662,809
25 February 2010 90,000 387.4210 34,867,890
26 February 2010 85,000 386.0500 32,814,250
Accumulated under 1,811,000 694,305,064
the programme
With the transactions stated above, Novo Nordisk owns a total of 32,082,298
treasury shares, corresponding to 5.2% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Klaus Bülow Davidsen
Tel: (+45) 4442 3450 Tel: (+45) 4442 3176
ekh@novonordisk.com klda@novonordisk.com
<mailto:ekh@novonordisk.com> <mailto:klda@novonordisk.com>
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
<mailto:krop@novonordisk.com>
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
<mailto:secl@novonordisk.com> <mailto:hrmm@novonordisk.com>
Company Announcement no 12 / 2010
[HUG#1389574]
